学会Official

第49回日本骨髄腫学会学術集会

The 49th Annual Meeting of the Japanese Society of Myeloma

2024年 5月31日（金）・6月1日（土）・6月2日（日）

会 場
福岡国際会議場
会 長
髙松　泰
MENU

Program

    • ■You can check the Schedule (PDF) below.
    May 31st (Friday), June 1st (Saturday), June 2nd (Sunday), 2024/Schedule (PDF)
    • Presidential Lecture
      June 1 (Sat.), 2024 13:30ー14:00
      Room1 (5F 501)
      Chair

      Masahiro Abe（Kawashima Hospital）

      Speaker

      Yasushi Takamatsu（Medical Oncology, Hematology and Infectious Diseases, Dept. of Internal Medicine, Fukuoka University）

    • International Symposium

      【English Session】

      June 1 (Sat.), 2024 10:40ー11:50
      Room1 (5F 501)
      Chairs

      Hiroshi Kosugi（Dept. of Hematology, Ogaki Municipal Hospital）

      Shinsuke Iida（Dept. of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences）

      「Current status and future prospects of treatment for myeloma - regarding the risk-adapted therapy」
      Speaker

      Shuji Ozaki（Dept. of Hematology, Tokushima Prefectural Central Hospital）

      「Current therapeutic options and the clinical outcomes of myeloma in Korea」
      Speaker

      Sung-Hoon Jung（Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Republic of Korea）

      「Prospects for future treatment strategy for myeloma, especially regarding the risk adapted therapy」
      Speaker

      Philippe Moreau（International Myeloma Society/Clinical Hematology, the University Hospital of Nantes/Translational Research Program in Hematology and Oncology, the University Hospital of Nante）

    • Symposium

      Symposium 1 「Therapies targeting the immune microenvironment」

      【English Session】

      June 1 (Sat.), 2024 09:00ー10:30
      Room1 (5F 501)
      Chairs

      Hideto Tamura（Division of Diabetes, Endocrinology and Hematology, Dept. of Internal Medicine, Dokkyo Medical University Saitama Medical Center）

      Michiko Ichii（Osaka University Graduate School of Medicine, Dept. of Hematology and Oncology）

      「The role of tumor microenvironment in myeloma treatment」
      Speaker

      Michiko Ichii（Osaka University Graduate School of Medicine, Dept. of Hematology and Oncology）

      Speaker

      Nikhil Munshi（Harvard Medical School, Dana-Farber Cancer Institute）

      Speaker

      Gareth Morgan（Perlmutter Cancer Center, New York University Langone）

      「Mechanisms of impairment of therapeutic efficacy of BCMA-targeting immunotherapies by osteoclasts」
      Speaker

      Harada Takeshi（Dept. of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences）

      Symposium 2 「Control and prevention of infectious diseases」
      June 1 (Sat.), 2024 09:00ー10:30
      Room3 (4F 411・412）
      Chairs

      Kazuki Tanimoto（Dept. of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital ）

      Tomohiko Kamimura（Dept. of Hematology,Harasanshin Hospital）

      「Management of infectious diseases in patients with multiple myeloma」
      Speaker

      Yoshihiro Eriguchi（Kyushu University Hospital, Dept. of Clinical Immunology and Rheumatology/Infectious Disease）

      「Management for bacterial infection in myeloma」
      Speaker

      Kazuhito Suzuki（The Jikei University School of Medicine, Division of Clinical Oncology and Hematology）

      「Management of fungal infections in multiple myeloma」
      Speaker

      Kentaro Serizawa（Dept. of Hematology and Rheumatology, Faculty of Medicine, Kindai University）

      「Viral infections in patients with multiple myeloma in the novel agent era: focus on herpes simplex virus, varicella-zoster virus, and cytomegalovirus」
      Speaker

      Masuho Saburi（Oita Prefectural Hospital Dept. of Hematology）

      Symposium 3 「New treatments（CAR-T/bispecific antibody）」

      【English Session】

      June 1 (Sat.), 2024 14:10ー15:40
      Room1 (5F 501)
      Chairs

      Tadao Ishida（Dept. of Hematology,Japanese Red Cross Medical Center）

      Junya Kuroda（Division of Hematology and Oncology, Dept. of Medicine,Kyoto Prefectural University of Medicine）

      「Idecabtagene Vicleucel (ide-cel) vs Standard Regimens (SR) in Patients (pts) with TCE RRMM: Updated KarMMa-3 Analysis」
      Speaker

      Shinsuke Iida（Dept. of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences）

      「Infectious complications of bispecific antibodies for multiple myeloma treatment」
      Speaker

      Ja Min Byun（Seoul National University Hospital）

      「Overview of bispecific antibody therapy in relapsed/refractory multiple myeloma」
      Speaker

      Mohamad Mohty（Sorbone University, Saint-Antoine Hospital）

      「Overview of CAR-T therapy」
      Speaker

      Nikhil Munshi（Harvard Medical School, Dana-Farber Cancer Institute）

      Symposium 4 「Geriatric assessments and rehabilitation」
      June 1 (Sat.), 2024 14:10ー15:40
      Room3 (4F 411・412）
      Chairs

      Hidenori Sasaki（Medical Oncology, Hematology and Infectious Diseases, Dept. of Internal Medicine, Fukuoka University）

      Satoshi Kamada（Dept. of Rehabilitationt,Fukuoka University Hospital）

      「The Necessity of Geriatric Assessments and Frailty Scores for Tailored Therapy in Multiple Myeloma Patients」
      Speaker

      Ji Yun Lee（Dept. of Internal Medicine,Seoul National University Bundang Hospital）

      「GNRI (geriatric nutritional risk index) in elderly patients with multiple myeloma」
      Speaker

      Kazuhito　Suzuki（The Jikei University School of Medicine, Division of Clinical Oncology and Hematology）

      「Enhancing patient care: integrating geriatric assessments for patients with multiple myeloma」
      Speaker

      Shohei Togashi （Dept. of Rehabilitation National Hospital Organization Hiroshima-Nishi Medical Center）

      「Management of elderly myeloma or metastatic bone tumor patients」
      Speaker

      Satoshi Kamada（Dept. of Rehabilitationt,Fukuoka University Hospital）

      「Discharge support hospital’s efforts to support the discharge of myeloma patients」
      Speaker

      Yoshiki Yamaguchi（Murakamikarindoh Hospital）

      「Discharge support for patients at high risk of pathological fracture through multidisciplinary collaboration」
      Speaker

      Shohei Sakamoto（Hakujyuji Hospital）

      Symposium 5 「Therapeutic management of bone lesions」
      June 2 (Sun.), 2024 9:00ー10:30
      Room1 (5F 501)
      Chairs

      Takeshi Harada （Dept. of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences）

      Yuichi Horigome（Dept. of Hematology, Kitasato University Hospital）

      「MM-bone interaction: from pathogenesis to treatment」
      Speaker

      Takeshi Harada（Dept. of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences）

      「Treatment of painful vertebral body fracture in patient with multiple myeloma : The orthopedic surgeon’s perspective.」
      Speaker

      Hidetake Matsuzaki（Department of Orthopedic surgery, National Hospital Organization Disaster Medical Center）

      「Imaging diagnosis of bone lesions in multiple myeloma」
      Speaker

      Miyuki Takasu（Dept. of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital）

      「Rehabilitation for patients with neoplastic bone lesions」
      Speaker

      Akira Kido（Department of Rehabilitation Medicine, Nara Medical University）

      Symposium 6 「Multi-professional collaboration and team medical care」
      June 2 (Sun.), 2024 9:00ー10:50
      Room3 (4F 411・412）
      Chairs

      Naoaki Nishimura（Dept. of Pharmacy, JCHO Kyushu Hospital ）

      Irusun Cye（Dept. of Hematology, NHO Kyushu Cancer Center）

      「Interprofessional collaboration for team medical care to patients during hospitalization and outpatient care after discharge」
      Speaker

      Noriko Yokota（Dept. of Nursing, Harasanshin Hospital）

      「Advanced medication management and patient support in multiple myeloma treatment」
      Speaker

      Masato Komuro（Center for Medical Informatics Intelligence, Center Hospital of the National Center for Global Health and Medicine）

      「The involvement of hospital pharmacists in transitioning from inpatient to outpatient treatment.」
      Speaker

      Tomoaki Eto（Department of Pharmacy, NHO Kyushu Cancer Center）

      「Collaboration regarding home care」
      Speaker

      Naoko Ishibashi（Nursing Department, Fukuoka Red Cross Hospital）

      「Roles of specialized hematology clinics in regional hematology care」
      Speaker

      Kensuke Ohta（Medical Corporation LIGARE, Hematology Ohta Clinic, Shinsaibashi）

    • Educational Seminar
      June 2 (Sun.), 2024 13:00ー13:40
      Room3 (4F 411・412）
      Chairs

      Yoshiaki Kuroda（Dept. of Hematology, National Hospital Organization Hiroshima-Nishi Medical Center）

      Shin-ichi Fuchida（JCHO Kyoto Kuramaguchi Medical Center）

      「Biological and clinical features of proteasome inhibitors and management of adverse effects」
      Speaker

      Shigeki Ito（Hematology & Oncology, Dept. of Internal Medicine, Iwate Medical University School of Medicine）

      「Immunomodulatory drugs (IMiDs) in multiple myeloma : characteristics, and management of the adverse event」
      Speaker

      Emiko Sakaida（Dept. of Hematology, Chiba University Hospital）

    • Patient and Public Involvement Program
      June 2 (Sun.), 2024 14:00ー15:30
      Room3 (4F 411・412)
      「Promoting shared decision making for patients to live well with myeloma」
      Chairs

      Yasushi Takamatsu（Medical Oncology, Hematology and Infectious Diseases, Dept. of Internal Medicine, Fukuoka University）

      Sachiko Shibata（Myeloma Patients and Families Association Fukuoka Orison）

      「Why is shared decision making important?」
      Speaker

      Yasushi Takamatsu（Medical Oncology, Hematology and Infectious Diseases, Dept. of Internal Medicine, Fukuoka University）

      「Results of survey for myeloma patients and their families.」
      Speaker

      Sachiko Shibata（Myeloma Patients and Families Association Fukuoka Orison）

      「What do patients expect? From the point of view of patients receiving treatment for myeloma.」
      Speaker

      Yasuo Houri（Myeloma Patients and Families Association Fukuoka Orison）

      Speaker

      Noriko Matsuura（Hamakko (Multiple Myeloma Patients and Families Meeting)）

      「Activities of patient associations and patient support groups.」
      Speaker

      Akiko Ikeda（NPO CancerNet Japan/(Hamakko (Multiple Myeloma Patients and Families Meeting)）

      「General discussion」
    • Plenary Session
      June 2 (Sun.), 2024 15:40ー16:40
      Room1 (5F 501)
      Chairs

      Masahiro Abe（Kawashima Hospital）

      Chiaki Nakaseko（International University of Health and Welfare School of Medicine, Dept. of Hematology）

      「Development of off-the-shelf anti-CD38-CAR-T therapy using iPS-derived cytotoxic T cells for the treatment of myeloma」
      Speakers

      Yuji Hattori（Fujita Health University　International Center for Cell and Gene Therapy）

      「IL-6-induced ELL2 governs myeloma transcriptional program」
      Speaker

      Hiroto Ohguchi （Division of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University）

      「Understanding the structure of the microenvironments in multiple myeloma with a focus on blood vessels」
      Speaker

      Kensuke Hachiya （Dept. of Signal Transduction, Research Institute for Microbial Diseases, Osaka University）

      「Analysis of circulating plasma cells (CPCs) in smoldering multiple myeloma and MGUS patients」
      Speaker

      Atsushi Uehara（Dept. of Hematology and Oncology, Kameda Medical Center）

      「Retrospective analysis of the incidence of herpes zoster and the patients' backgrounds in transplant-ineligible NDMM patients receiving D-Rd」
      Speaker

      Yuichi Horigome （Dept. of Hematology, Kitasato University Hospital）

    • Oral Session
      Oral Session 1 「Basic and clinical research 1」
      June 1 (Sat.), 2024 10:40ー11:50
      Room3 (4F 411・412）
      Chairs

      Yutaka Hattori（Keikokai Medical Corp P-one Clinic）

      Akira Sakai（Dept. of Radiation Life Sciences,Fukushima Medical University School of Medicine ）

      Oral Session 2 「Basic and clinical research 2」
      June 2 (Sun.), 2024 10:40ー11:50
      Room1 (5F 501)
      Chairs

      Hiroshi Handa（Dept. of Hematology, Gunma University Hospital, Gunma, Japan）

      Yoichi Imai（Dept. of Hematology and Oncology,Dokkyo Medical University,Japan）

      Oral Session 3 「Multidisciplinary collaboration」
      June 2 (Sun.), 2024 11:00ー11:50
      Room3 (4F 411・412)
      Chairs

      Yasuhito Terui（Dept. of Hematology, Saitama Medical University Hospital）

      Ryosuke Ogawa（Dept. of Hematology and Oncology,JCHO Kyushu Hospital ）

      Oral Session 4 「Treatment」
      June 2 (Sun.), 2024 14:00ー15:30
      Room1 (5F 501)
      Chairs

      Hirohiko Shibayama（Dept. of Hematology,National Hospital Organization Osaka National Hospital）

      Kazutaka Sunami（Dept. of Hematology, NHO Okayama National Hospitall）

    • Poster Session
      June 1 (Sat.), 2024 18:00ー19:00
      Poster Room (4F 409・410)
    • Sponsored Seminars
      Morning Seminar 1
      June 2 (Sun.), 2024 8:10ー8:50
      Room1 (5F 501)
      Chair

      Mineo Kurokawa（Dept. of Hematology & Oncology,Graduate School of Medicine, The University of Tokyo）

      「Pitfalls of M protein Detection by Immunofixation in plasma cell dyscrasias.」
      Speaker

      Yawara Kawano（Dept. of Hematology, Rheumatology, and Infecti ous Diseases, Graduate School of Medical Sciences, Kumamoto University）

      Co-hosting
      SEBIA JAPAN K.K.
      Morning Seminar 2
      June 2 (Sun.), 2024 8:10ー8:50
      Room2 (5F 502・503)
      Chair

      Masaki Iino（Yamanashi Prefectural Central Hospital）

      「The importance of minimal residual disease (MRD) analysis in myeloma treatment in the immunotherapy era- focusing on the characteristics and usefulness of Multicolor 10 -」
      Speaker

      Yoichi Imai （Dept. of Hematology and Oncology, Dokkyo Medical University）

      Co-hosting
      LSI Medience Corporation
      Morning Seminar 3
      June 2 (Sun.), 2024 8:10ー8:50
      Room3 (4F 411・412)
      Chair

      Kensuke Ohta（Medical Corporation LIGARE, Hematology Ohta Clinic, Shinsaibashi）

      「The importance of achieving well-being for multiple myeloma patients and the significance of maintenance therapy」
      Speaker

      Ryosuke Ogawa（Dept. of Hematology and Oncology,JCHO Kyushu Hospital）

      Speaker

      takashi Ikeda（Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan）

      Co-hosting
      Takeda Pharmaceutical CO., LTD.
      Luncheon Seminar 1
      June 1 (Sat.), 2024 12:00ー12:50
      Room1 (5F 501)
      Chair

      Ichiro Hanamura（Division of Hematology.Dept. of Internal Medicine,Aichi Medical University,Japan）

      「Clinical Landscape and Future Horizons in Multiple Myeloma Therapy: Advancing from MAIA and ALCYONE」
      Speaker

      Taku Kikuchi（Japanese Red Cross Medical Center）

      Co-hosting
      Janssen Pharmaceutical K.K.
      Luncheon Seminar 2
      June 1 (Sat.), 2024 12:00ー12:50
      Room2 (5F 502・503)
      Chair

      Naoki Hosen（Osaka University Graduate School of Medicine, Dept. of Hematology and Oncology）

      「Future Treatment Landscape of multiple myeloma」
      Speaker

      Tadao Ishida（Dept. of Hematology, Japanese Red Cross Medical Center）

      Co-hosting
      AbbVie GK
      Luncheon Seminar 3
      June 1 (Sat.), 2024 12:00ー12:50
      Room3 (4F 411・412)
      Chair

      Koji Nagafuji（Division of Hematology and Oncology, Dept. of Medicine,Kurume University School of Medicine.）

      「Significance of SARS-CoV-2 infection in clinical setting in patients with hematologic malignancies」
      Speaker

      Akihiro Tomita（Dept. of Hematology,Fujita Health University）

      Co-hosting
      AstraZeneca K.K.
      Luncheon Seminar 4
      June 2 (Sun.), 2024 12:00ー12:50
      Room1 (5F 501)
      Chair

      Hiroshi Handa（Dept. of Hematology, Gunma University Hospital, Gunma, Japan）

      「New options for treatment of relapsed or refractory multiple myeloma (RRMM)」
      Speaker

      Sunami Kazutaka（Dept. of Hematology, NHO Okayama National Hospitall）

      Co-hosting
      Pfizer Japan Inc.
      Luncheon Seminar 5
      June 2 (Sun.), 2024 12:00ー12:50
      Room2 (5F 502・503)
      Chair

      Yasushi Isobe（Medical Oncology, Hematology and Infectious Diseases, Dept. of Internal Medicine, Fukuoka University）

      「Secondary hypogammaglobulinemia and infection prevention in patients with multiple myeloma -The significance of immunoglobulin replacement therapy－」
      Speaker

      Yoshiaki Kuroda（Dept. of Hematology and Oncology NHO Hiroshimanishi Medical Center）

      Co-hosting
      CSL Behring K.K.
      Luncheon Seminar 6
      June 2 (Sun.), 2024 12:00ー12:50
      Room3 (4F 411・412)
      Chair

      Hirohiko Shibayama（Dept. of Hematology,National Hospital Organization Osaka National Hospital）

      「Significance of monitoring serum free light chain in myeloma kidney and MGRS-associated renal lesions」
      Speaker

      Shinichi Mizuno（Japan Community Health care Organization Sendai Hospital, Dept. Nephrology）

      Co-hosting
      Thermo Fisher Diagnostics K.K.
      Evening Seminar 1
      May 31 (Fri.), 2024 17:00ー17:50
      Room1 (5F 501)
      Chair

      Masahiro Abe（Kawashima Hospital/Professor Emeritus of Tokushima University）

      「Updates in RRMM: Evolving Treatment Strategies for Sequencing Immune-based Therapies」
      Speaker

      Nikhil Munshi（Harvard Medical School, Dana-Farber Cancer Institute）

      Co-hosting
      Bristol-Myers Squibb K.K.
      Evening Seminar 2
      June 1 (Sat.), 2024 17:00ー17:50
      Room1 (5F 502・503)
      Chair

      Emiko Sakaida（Dept. of Hematology, Chiba University Hospital）

      「Clinical significance of immune-based therapy and iMiDs sequences from the perspective of chromosomal abnormalities and immune microenvironment in multiple myeloma」
      Speaker

      Akihiro Kitadate（Dept. of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan）

      「Optimal introduction of CAR-T therapy for triple-class exposed RRMM」
      Speaker

      Naoya Mimura（Dept. of Transfusion Medicine and Cell Therapy, Chiba University Hospital）

      Co-hosting
      Bristol-Myers Squibb K.K.
      Evening Seminar 3
      June 1 (Sat.), 2024 17:00ー17:50
      Room2 (5F 502・503)
      Chair

      Junya Kuroda（Division of Hematology and Oncology,Kyoto Prefectural University of Medicine Graduate School of Medical Science,Japan）

      「Treatment strategy for Waldenström’s macroglobulinemia in 2024 and future prospects」
      Speaker

      Naohiro Sekiguchi（Dept. of Hematology, National Hospital Organization Disaster Medical Center）

      Co-hosting
      ONO PHARMACEUTICAL CO., LTD.
      Evening Seminar 4
      June 1 (Sat.), 2024 17:00ー17:50
      Room3 (4F 411・412)
      Chair

      Chihiro Shimazaki（JCHO Kyoto Kuramaguchi Medical Center,honorary director of the clinic）

      「Rationale of using Isatuximab in second-line treatment：explaining efficacy and safety from basic and clinical perspectives」
      Speaker

      Keichiro Mihara（Fujita Health University　International Center for Cell and Gene Therapy/Cellular Immunotherapies for Cancer）

      Speaker

      Shigeki Ito（Division of Hematology and Oncology, Dept. of Internal Medicine, Iwate Medical University School of Medicine）

      Co-hosting
      Sanofi K.K.
      Corporate Seminar 1
      June 1 (Sat.), 2024 15:50ー16:40
      Room1 (5F 501)
      Chair

      Hideto Tamura（Dokkyo Medical University Saitama Medical Center,Japan）

      「Optimizing the outcome of newly diagnosed multiple myeloma」
      Speaker

      Gareth Morgan（Perlmutter Cancer Center）

      Co-hosting
      Janssen Pharmaceutical K.K.
      Corporate Seminar 2
      June 1 (Sat.), 2024 15:50ー16:40
      Room3 (4F 411・412)
      Chair

      Yusuke Furukawa（Center for Medical Education,Teikyo University of Science）

      「Role of carfilzomib for relapsed/refractory multiple myeloma in the immunotherapy era」
      Speaker

      Masuho Saburi（Oita Prefectural Hospital Department of Hematology）

      Co-hosting
      ONO PHARMACEUTICAL CO., LTD.
      Corporate Seminar 3
      June 2 (Sun.), 2024 13:00ー13:50
      Room1 (5F 501)
      Chair

      Shinsuke Iida（Dept. of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences）

      「BCMA-targeted therapies: an update」
      Speaker

      Mohamad Mohty（Sorbone University, Saint-Antoine Hospital）

      Co-hosting
      Pfizer Japan Inc. Medical Affairs
      Corporate Seminar 4
      June 2 (Sun.), 2024 13:00ー13:50
      Room2 (5F 502・503)
      Chair

      Toshihiro Miyamoto（Kanazawa University Hematology）

      「For physicians considering patient referral: Key factors influencing the safety, efficacy, and manufacturing of BCMA CAR T in clinical practic」
      Speaker

      Masaki Ri（Dept. of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences）

      「How to Maximize the Benefits of BCMA CAR T Therapy: Insights from Real-World Clinical Experience」
      Speaker

      Satoshi Yoshihara（Dept. of Respiratory Medicine and Hematology, Hyogo Medical University）

      Co-hosting
      Bristol-Myers Squibb K.K.Japan Medical
    1. ヤンセンファーマ株式会社
    2. PfizerPro ヘマトロジー | Hematology